A phase II trial of the super-enhancer inhibitor Minnelide™ in advanced refractory adenosquamous carcinoma of the pancreas.
Future Oncol
; 18(20): 2475-2481, 2022 Jun.
Article
en En
| MEDLINE
| ID: mdl-35535581
Adenosquamous carcinoma of the pancreas (ASCP) is a rare and highly aggressive variant of pancreatic cancer, with limited treatment options. Changes in activation of DNA elements called super-enhancers drive the growth of ASCP. Minnelide™ is an oral drug that blocks the super-enhancer network and is safe to give to patients with advanced cancer. This trial is designed to determine whether Minnelide can shrink tumors in patients with ASCP who have already received at least one previous treatment for their cancer. Clinical Trial Registration: NCT04896073 (ClinicalTrials.gov).
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Pancreáticas
/
Carcinoma Adenoescamoso
/
Carcinoma Ductal Pancreático
Límite:
Humans
Idioma:
En
Año:
2022
Tipo del documento:
Article